Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

Official record

Identifier

NCT07609225

Recruiting locations

country

United States

Interventions studied

3'-Deoxy-3'-[18F]-fluorothymidineChemical-shift-encoded MRI

Lead sponsor

University of Wisconsin, Madison

Target enrolment

15 participants

Study type

INTERVENTIONAL

Phase

Early Phase 1

Status

Not yet recruiting

First posted

May 27, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

MALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Ability to understand and the willingness to sign a written informed consent document.
* Patients must be informed of the experimental nature of the study and its potential risks, and must sign institutional review board (IRB) approved consent form indicating such understanding.
* Individuals at least 18 years of age.
* Patients must have histologically or cytologically confirmed prostate cancer.
* Patients must be clinically deemed appropriate for standard of care Lu-177 PSMA RPT.
* Eastern Cooperative Oncology Group (ECOG) performance 0-2
* Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging.

Exclusion Criteria:

* Patients receiving any concurrent therapy known to impact bone marrow (either stimulate or suppress the marrow, for example G-CSF).
* Patients treated with chemotherapy or 223Ra radiotherapy within 4 weeks.
* All acute toxic effects of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to a grade ≤ 2 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 (CTCAE).
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements per treating physician discretion.

Indexed under

Prostate Cancer